Skip to main content
Clinical Trials/NCT02131389
NCT02131389
Unknown
Not Applicable

Non-Randomized, Multi-Site, Post-Market Study of the ICONACY I-Hip System (Protocol No. PS-1001)

Iconacy Orthopedic Implants, LLC.2 sites in 1 country500 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Degenerative Joint Disease
Sponsor
Iconacy Orthopedic Implants, LLC.
Enrollment
500
Locations
2
Primary Endpoint
Radiographic Success as a Measure of Radiolucency and Component Migration
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the use and efficacy of the I-Hip for primary total hip replacement surgery.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
December 2019
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • A candidate for primary hip replacement on this operative hip.
  • Is 30 to 80 years of age.
  • Has hip joint disease related to one or more of the following:
  • Degenerative joint disease, (including osteoarthritis or post-traumatic arthritis)
  • Avascular Necrosis (AVN).
  • Will be available for evaluation for the duration of the study.
  • Is able and willing to speak and read English, read and sign the informed consent, fill out the WOMAC and Patient Satisfaction questionnaires, and follow all study procedures.

Exclusion Criteria

  • Is younger than 30 years of age or older than 80 years of age.
  • Has undergone partial hip replacement or previous ORIF (open reduction internal fixation of femur or acetabulum).
  • Has undergone total hip replacement on this hip in the past (no revisions allowed in study).
  • Infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection.
  • Is currently experiencing radicular pain from the spine down operative leg.
  • Has participated in an IDE/IND clinical investigation with an investigational product in the last three months, or is involved in any personal injury litigation, medical-legal or worker's compensation claim.
  • Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires.
  • Has been diagnosed with fibromyalgia or has a significant neurological or musculoskeletal disorder or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, Charcot disease).
  • Has been diagnosed with Paget's disease or Congenital hip deformity (dysplasia and/or dislocation).
  • Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.)

Outcomes

Primary Outcomes

Radiographic Success as a Measure of Radiolucency and Component Migration

Time Frame: 2 years

A subject will be considered a failure for Overall Radiographic Success if one or more of the below conditions are met: The subject will be considered a RADIOGRAPHIC FAILURE if: 1. there is a complete radiolucent line\> 3mm wide at the bone/cement interface or 2. there is a \>5 degree migration (shift) of the component or 3. there is a \>5 mm migration (shift) of the component.

Improvement of Harris Hip Score (with Charnley Score and other comorbidities considered)

Time Frame: 2 years

Patient satisfaction clinical assessment utilizing questionnaire

Time Frame: 2 years

Clinical assessment of patient satisfaction will be made by utilizing a Patient Satisfaction (PS) questionnaire.

Secondary Outcomes

  • Revision of Implant Prosthesis as a Measure of Efficacy(5 years)

Study Sites (2)

Loading locations...

Similar Trials